Skip to main content
RENERVE LIMITED logo

RENERVE LIMITED — Investor Relations & Filings

Ticker · RNV ISIN · AU0000358616 ASX Manufacturing
Open in API
Filings indexed 134 across all filing types
Latest filing 2025-07-10 Capital/Financing Update
Country AU Australia
Listing ASX RNV

About RENERVE LIMITED

https://renerve.com.au/

Renerve Limited is a medical technology company focused on the development and commercialization of advanced solutions for tissue repair and regeneration. The company specializes in peripheral nerve repair through its proprietary NervAlign platform. This technology utilizes a specialized decellularization process to create high-quality nerve grafts derived from porcine tissue. These grafts are designed to provide a natural scaffold that supports and guides axonal regrowth across nerve gaps, offering an alternative to traditional autografts. By maintaining the structural integrity and biochemical cues of the extracellular matrix, Renerve's products aim to improve functional recovery outcomes for patients suffering from traumatic nerve injuries. The company's research and development efforts are centered on expanding the applications of its tissue engineering platform to address various clinical needs in regenerative medicine.

Recent filings

Filing Released Lang Actions
Proposed issue of securities - RNV 5 pages 17.2KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B - Proposed issue of securities' and details a proposed placement or other type of securities issue by RENERVE LIMITED. It includes specifics such as the number of securities, issue date, consideration, and compliance with ASX Listing Rules. There is no financial performance data, earnings information, or management discussion. The content is focused on the announcement of a capital raising or securities issuance event. This matches the definition of a Capital/Financing Update (CAP). The document length is sufficient and contains detailed information about the securities issue, not just a brief announcement or reference to a report, so it is not an RPA or RNS. Therefore, the correct classification is CAP with high confidence.
2025-07-10 English
Investor presentation - the Berkeley Biologics Partnership 15 pages 888.4KB
Investor Presentation Classification · 95% confidence The document is titled as an "Investor Update" dated June 2025 and contains detailed information about the company's product portfolio, market strategy, partnership announcements, sales and distribution presence, clinical validation, and near-term milestones. It includes forward-looking statements, disclaimers, and investment highlights. The content is structured as a presentation aimed at investors, focusing on business strategy, product development, market opportunities, and partnership details rather than detailed financial statements or regulatory filings. There is no indication of it being a full annual or quarterly report, audit report, earnings release, or legal proceeding. The document is not a brief factsheet or a voting result announcement. It is clearly a detailed presentation for investors about the company's current status and future plans. Therefore, the most appropriate classification is Investor Presentation (IP).
2025-06-02 English
Expands Product Portfolio with Berkley partnership / Webinar 4 pages 297.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 2 June 2025 about ReNerve Limited entering a strategic partnership with Berkeley Biologics to expand its product portfolio. It includes details about the partnership, product launches, market information, and a webinar invitation. There are no financial statements, quarterly or annual results, or detailed financial analysis present. The document is a corporate announcement about a business development and upcoming webinar, not a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is a typical corporate news release announcing a strategic partnership and product expansion. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback for general regulatory announcements and miscellaneous filings that do not fit other categories.
2025-06-01 English
ReNerve receives market approval in Bahrain 3 pages 255.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 28 May 2025 about ReNerve Limited receiving marketing approval in Bahrain for its NervAlign Nerve Cuff product. It discusses the market opportunity, partnership details, and company background. There are no financial statements, quarterly or annual results, or detailed financial data. The document is a corporate announcement about a regulatory/market approval event rather than a financial report or earnings release. It is not a report publication announcement since it contains substantive information about the approval and market context. Therefore, the document fits best into the category of a Regulatory Filing (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2025-05-27 English
Change of Director's Interest Notice - S Cooper 2 pages 36.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director's Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in relevant interests in securities, including the number of shares held before and after the change, the nature of the interest, and transaction details. This is a report of personal share transactions by a company director, which fits the definition of Director's Dealing filings. The document length is short and focused solely on director share transactions, with no financial statements or other report content. Therefore, the appropriate classification is Director's Dealing (DIRS).
2025-05-08 English
Quarterly Investor Presentation 19 pages 2.1MB
Interim / Quarterly Report Classification · 95% confidence The document is a detailed quarterly investor update presentation from ReNerve Ltd dated May 2025. It includes extensive information about the company's product portfolio, market opportunities, sales highlights, global expansion, clinical studies, and key hires. The content is focused on business strategy, product development, market positioning, and sales performance for a quarter, which aligns with a quarterly report. There are no indications that this is a full annual report, audit report, earnings release, or a regulatory filing. The document is not a transcript, nor a voting result, nor a capital update. It is a comprehensive quarterly update with substantive financial and operational data, consistent with an Interim / Quarterly Report (IR). The document length (15,000 characters) and detailed content confirm it is not merely an announcement or a short summary, so it is not an RPA or RNS. Therefore, the best classification is Interim / Quarterly Report (IR). Q3 2025
2025-05-06 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.